Pharmacokinetics of 2-oxothiazolidine-4-carboxylate, a cysteine prodrug, and cysteine

Journal of Clinical Pharmacology

Volumn 38, Issue 10, 1998, Pages 945-950

  Gwilt, Peter R ^a   Radick, Lorraine E ^b   Li, Xiao Yan ^b   Whalen, John J ^b   Leaf, Cynthia D ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Transcend Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; CYSTEINE; GLUTATHIONE DISULFIDE; PRODRUG;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG POTENCY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICHAELIS CONSTANT; NORMAL HUMAN; OXIDATIVE STRESS; TISSUE INJURY;

EID: 0031786731     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04391.x     Document Type: Article

References (18)

1. McNaughton PD, Evans TW: Adult respiratory distress syndrome. Lancet 1992:339:469-472.
2. Raju PA, Herzenberg LA, Roederer M: Glutathione precursor and antioxidant activities of N-acetylcysteine and oxothiazolidine carboxylate compared in vitro studies of HIV replication. AIDS Res Hum Retroviruses 1994;10:961-967.
3. Simonian NA, Coyle JT: Oxidative stress in neurodegenerative diseases. Annu Rev Pharmacol Toxicol 1996;36:83-106.
4. Halliwell B: The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 235:118-126.
5. Meister A: Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol Ther 1991;51:155-194.
6. Andersen ME, Meister A: Intracellular delivery of cysteine. Methods Enzymol 1987;143:313-325.
7. Leaf CD, Pace GW: Development of a novel glutathione repleting agent, L-2-oxothiazolidine-4-carboxylic acid (procysteine). Exp Opin Invest Drugs 1994:3:1293-1302.
8. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE, the Antioxidants in ARDS Study Group: A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997:164-172.
9. Kalyjian RC, Skowron G, Emgushov R, Chance M, Spell SA, Borum PR, et al: A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects. J Acquir Immune Defic Syndr 1994;7:369-374.
10. Webb LW, Gechman M, Story K: Determination of L-2-oxothiazolidine-4-carboxylic acid (procysteine) in human plasma by high-performance liquid chromatography. J Chromatogr B 1994;654:257-262.
11. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM: Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993;39:263-271.
12. NONMEM Project Group: NONMEM 77. Version IV, Level 2. San Francisco: University of California at San Francisco, 1992.
13. Yamaoka K, Nakagawa T, Uno T: Application of Akaike's Information Criterion in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
14. Porta P, Aebi S, Summer K, Sauterburg BH: L-2-oxothiazolidine-4-carboxylate acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. JPharmacol Exp Ther 1991;257:331-334.
15. Garcia-Ruiz C, Fernandez JC, Kaplowitz N: Bidirectional mechanism of plasma transport of reduced glutathione in intact rat hepatocytes and membrane vesicles. J Biol Chem 1992;267: 22256-22264.
16. Butterworth M, Upshall DG, Hobbs M, Cohen GM: Elevation of cysteine and replenishment of glutathione by cysteine isopropylester and other cysteine precursors. Biochem Pharmacol 1993; 45:1769-1774.
17. Flanagan RJ, Meredith JJ: Use of N-acetylcysteine in clinical toxicology. Am J Med 1991;Suppl 3C:131S-139S.
18. Banks MF, Stipanuk MH: The utilization of N-acetylcysteine and 2-oxothiazolidine-4-carboxylate by rat hepatocytes is limited by their rate of uptake and conversion to cysteine. J Nutr 1996; 124:378-387.